Patents by Inventor Peter Edman
Peter Edman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11953938Abstract: The present technology proposes techniques for generating globally coherent timestamps. This technology may allow distributed systems to causally order transactions without incurring various types of communication delays inherent in explicit synchronization. By globally deploying a number of time masters that are based on various types of time references, the time masters may serve as primary time references. Through an interactive interface, the techniques may track, calculate and record data relative to each time master thus providing the distributed systems with causal timestamps.Type: GrantFiled: May 10, 2022Date of Patent: April 9, 2024Assignee: Google LLCInventors: Peter Hochschild, Alexander Lloyd, Wilson Cheng-Yi Hsieh, Robert Edman Felderman, Michael James Boyer Epstein
-
Publication number: 20090081453Abstract: A low emissive camouflage flake including a metal layer having thermal reflective properties in, at least one side of the metal layer is coated with a colored coating having thermal transparency properties. A method for manufacturing low emissive camouflage flakes. A skin camouflage for providing visual and thermal camouflage to a user thereof. A method for manufacturing a skin camouflage for providing visual and thermal camouflage to a user thereof. A camouflage paint for providing visual and thermal camouflage to an object on which the paint is applied. A method for manufacturing a camouflage paint for providing visual and thermal camouflage to an object on which the paint is applied.Type: ApplicationFiled: February 1, 2008Publication date: March 26, 2009Applicant: SAAB ABInventors: Peter Edman, Johan Jersblad
-
Publication number: 20060014699Abstract: An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC—CH2—(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, a process for the preparation of such a pharmaceutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment and thromboembolism by using said formulation via nasal administration.Type: ApplicationFiled: November 11, 2003Publication date: January 19, 2006Applicant: AstraZeneca ABInventors: Peter Edman, Karin Wingstrand
-
Patent number: 6846801Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: GrantFiled: September 22, 1998Date of Patent: January 25, 2005Assignee: AstraZeneca ABInventors: Kjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 6794357Abstract: Disclosed herein are dry powder compositions comprising a pharmacologically active polypeptide and a surfactant, wherein at least 50% of the total mass of the polypeptide and the surfactant consists of primary particles having a diameter less than 10 microns. The compositions are suitable for inhalation from a dry powder inhaler device.Type: GrantFiled: October 24, 1996Date of Patent: September 21, 2004Assignee: AstraZeneca ABInventors: Kjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20040171550Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.Type: ApplicationFiled: March 3, 2004Publication date: September 2, 2004Applicant: AstraZeneca AB, a Swedish corporationInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20030216541Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: ApplicationFiled: March 27, 2003Publication date: November 20, 2003Applicant: AstraZeneca AB, a Swedish corporationInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20030211972Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: ApplicationFiled: March 27, 2003Publication date: November 13, 2003Applicant: AstraZeneca AB, a Sweden corporationInventors: Kjell Goran Erik Backstrom, Carlos Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 6632456Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.Type: GrantFiled: October 24, 1997Date of Patent: October 14, 2003Assignee: AstraZeneca ABInventors: Kjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 6610653Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.Type: GrantFiled: September 18, 2000Date of Patent: August 26, 2003Assignee: AstraZeneca ABInventors: Kjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20030064928Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mammalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates, of such particles.Type: ApplicationFiled: August 19, 2002Publication date: April 3, 2003Applicant: Astra Aktiebolag, a Sweden corporationInventors: Kjell Backstrom, Bjorn Wallmark, Magnus Dahlback, Peter Edman, Ann Johansson
-
Publication number: 20020115588Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mammalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.Type: ApplicationFiled: August 26, 1999Publication date: August 22, 2002Inventors: KJELL BACKSTROM, BJORN WALLMARK, MAGNUS DAHLBACK, PETER EDMAN, ANN JOHANSSON
-
Patent number: 6436902Abstract: The present invention relates to compositions and methods for pulmonary administration of full-length parathyroid hormone to mamnmalian hosts for the treatment of osteoporosis. Thus there is provided a therapeutic preparation comprising a human full-length parathyroid hormone, or homologues thereof, in the form of a dry powder suitable for inhalation in which at least 50% of said dry powder consists of (a) particles having a diameter of up to 10 microns; or (b) agglomerates of such particles.Type: GrantFiled: August 26, 1999Date of Patent: August 20, 2002Assignee: AstraZeneca ABInventors: Kjell Bäckström, Björn Wallmark, Magnus Dahlbäck, Peter Edman, Ann Johansson
-
Patent number: 6306440Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.Type: GrantFiled: August 6, 1997Date of Patent: October 23, 2001Assignee: AstraZeneca ABInventors: Kjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20010025037Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: ApplicationFiled: February 14, 2001Publication date: September 27, 2001Applicant: AstraZeneca ABInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Publication number: 20010003739Abstract: A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.Type: ApplicationFiled: December 6, 2000Publication date: June 14, 2001Applicant: AstraZeneca ABInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 6165976Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.Type: GrantFiled: May 5, 1998Date of Patent: December 26, 2000Assignee: Astra AktiebolagInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 6140308Abstract: Novel compounds which are a glucocorticosteroid (GCS) chemically bound to a sugar, having the general formulaGCS.sup.1 --O--Sugar.sup.1for colon- or ileum-specific delivery of the GCS to inflamed bowel mucosa, as well as processes for their preparation, pharmaceutical preparations containing the compounds and the use of said compounds in therapy.Type: GrantFiled: March 3, 1999Date of Patent: October 31, 2000Assignee: Aktiebolaget AstraInventors: Ralph Lennart Brattsand, Peter Edman, Thomas Hogberg, Stinabritt Nilsson, Bror Arne Thalen, Jan Erik Ulmius
-
Patent number: 5952008Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.Type: GrantFiled: May 19, 1997Date of Patent: September 14, 1999Assignee: AB AstraInventors: Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
-
Patent number: 5908833Abstract: Novel compounds which are a glucocorticosteroid (GCS) chemically bound to a sugar, having the general formulaGCS.sup.1 --O--Sugar.sup.1for colon- or ileum-specific delivery of the GCS to inflamed bowel mucosa, as well as processes for their preparation, pharmaceutical preparations containing the compounds and the use of said compounds in therapy.Type: GrantFiled: December 13, 1996Date of Patent: June 1, 1999Assignee: Aktiebolaget AstraInventors: Ralph Lennart Brattsand, Peter Edman, Thomas Hogberg, Stinabritt Nilsson, Bror Arne Thalen, Jan Erik Ulmius